Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (SonsInc.)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's diseaseAbstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the br... ...
Tập 4 Số 1 - Trang 575-590 - 2018
Alzheimer's disease drug development pipeline: 2018Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III.Results There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on hiện toàn bộ
Tập 4 Số 1 - Trang 195-214 - 2018
Alzheimer's disease drug development pipeline: 2017Abstract Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. Methods We assessed the agents in the AD pipeline as documented in hiện toàn bộ
Tập 3 Số 3 - Trang 367-384 - 2017
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain healthAbstract Cognitive decline leading to dementia represents a global health burden. In the absence of targeted pharmacotherapy, lifestyle approaches remain the best option for slowing the onset of dementia. However, older adults spend very little time doing moderate to vigorous exercise and spend a majority of time in sedentary behavior. Sedentary behavior has been li... ...
Tập 3 Số 3 - Trang 291-300 - 2017
Amyloid‐associated increases in longitudinal report of subjective cognitive complaintsAbstract Introduction To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. Methods Two hundred seventy‐ni...
Tập 4 - Trang 444-449 - 2018
Accelerating drug development for Alzheimer's disease through the use of data standardsAbstract Introduction The exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integrat...
Tập 3 - Trang 273-283 - 2017
Machine learning models to predict onset of dementia: A label learning approachAbstract Introduction The study objective was to build a machine learning model to predict incident mild cognitive impairment, Alzheimer's Disease, and related dementias from structured data using administrative and electronic health record sources. Methods A cohort of pat...
Tập 5 - Trang 918-925 - 2019
The My Active and Healthy Aging (My‐AHA) ICT platform to detect and prevent frailty in older adults: Randomized control trial design and protocolAbstract Introduction Frailty increases the risk of poor health outcomes, disability, hospitalization, and death in older adults and affects 7%–12% of the aging population. Secondary impacts of frailty on psychological health and socialization are significant negative contributors to poor outcomes for frail older adults. ...
Tập 4 - Trang 252-262 - 2018
Design of the ExCersion‐VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairmentAbstract There is evidence for a beneficial effect of aerobic exercise on cognition, but underlying mechanisms are unclear. In this study, we test the hypothesis that aerobic exercise increases cerebral blood flow (CBF) in patients with vascular cognitive impairment (VCI). This study is a multicenter single‐blind randomized controlled trial among 80 patients with VC... ...
Tập 3 - Trang 157-165 - 2017
Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence?Abstract Causation of Alzheimer's disease (AD) is not well understood. It is necessary to look beyond neuropathology to identify the underlying causes of AD and many other common neurological diseases. Lipid abnormalities are well documented in the preclinical phases of many neurological diseases including AD. Here, we use AD as an example to examine the role of lip... ...
Tập 5 - Trang 524-532 - 2019